In recent years, kinase targeted therapies have been developed that have shown improved efficacy in treatment of lung cancer compared to standard chemotherapy, e.g., epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors [17] and anaplastic lymphoma kinase (ALK) inhibitors [18]. This evidence concerns the gene ALK and lung carcinoma.